Explore

Companies

Drugs

About·Data Management·Terms·Privacy

Stay informed

© 2026 VivoSeq. All rights reserved.

Glycophos

(Sodium Glycerophosphate 216 MG/ML)

Small molecule

FFresenius Kabi Taiwan Ltd.

0

Indications

1

Total Trials

1

Active Trials

0

Competitors

1

FDA Application

NDA/BLA/ANDA regulatory filings

Clinical

Trials by Indication[1]

Hypophosphatemia1 trial

Effect of Hypophosphatemia on Neuro-excursion Efficiency During Mechanical Ventilator Weaning

Recruiting·PPeking Union Medical College··NCT06754670·70 enrolled

Regulatory

FDA Approval Timeline[3]

Jul 28, 2026

GLYCOPHOS

NDA NDA220381

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Sodium Glycerophosphate 216 MG/ML. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Sodium Glycerophosphate 216 MG/ML compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
OpenFDA — FDA approval records (NDA NDA220381). U.S. Food & Drug Administration.
[4]
SEC EDGAR — Fresenius Kabi Taiwan Ltd. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Company: FFresenius Kabi Taiwan Ltd.

Related News